coin-img-BTCBTC-1.13%coin-img-SOLSOL-1.04%coin-img-XRPXRP-2.54%coin-img-ETHETH-1.49%coin-img-ALPHAXALPHAX+5,424.80%coin-img-DEVERSEDEVERSE-71.78%coin-img-USDCUSDC+0.01%coin-img-TRXTRX+1.32%coin-img-BTCBTC-1.13%coin-img-SOLSOL-1.04%coin-img-XRPXRP-2.54%coin-img-ETHETH-1.49%coin-img-ALPHAXALPHAX+5,424.80%coin-img-DEVERSEDEVERSE-71.78%coin-img-USDCUSDC+0.01%coin-img-TRXTRX+1.32%coin-img-BTCBTC-1.13%coin-img-SOLSOL-1.04%coin-img-XRPXRP-2.54%coin-img-ETHETH-1.49%coin-img-ALPHAXALPHAX+5,424.80%coin-img-DEVERSEDEVERSE-71.78%coin-img-USDCUSDC+0.01%coin-img-TRXTRX+1.32%coin-img-BTCBTC-1.13%coin-img-SOLSOL-1.04%coin-img-XRPXRP-2.54%coin-img-ETHETH-1.49%coin-img-ALPHAXALPHAX+5,424.80%coin-img-DEVERSEDEVERSE-71.78%coin-img-USDCUSDC+0.01%coin-img-TRXTRX+1.32%
user-avatar
scanx.trade

Poly Medicure reports Q1FY27 revenue up 30.3% to ₹5,253.76 lacs; PAT at ₹852.74 lacs

AI Market Summary
Poly Medicure reported strong Q1FY27 topline momentum with revenue up 30.3% YoY, but consolidated PAT declined 8.4% and EPS fell, highlighting margin and consolidation effects despite operational growth. The quarter included incremental corporate actions (ESOP grants/allotments), a small Brazil acquisition, and management's stated focus on capacity expansion and doubling international sales. Market relevance is mainly idiosyncratic, with limited broader cross-asset read-through.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.17%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Poly Medicure reported Q1FY27 consolidated revenue up 30.3% year on year to 5,253.76 lacs. Net profit declined 8.4% to 852.74 lacs and earnings per share fell 7.6%. Separately, its subsidiary Polymed Brazil acquired 100% of Medyneo for 34.08 lacs.
Disclaimer: The content above is only the author's opinion and does not represent BingX’s stance. It shall not be construed as investment advice from BingX. For details, refer to the Terms and Conditions.
Stocks

Risk Warning

Cryptocurrencies and their derivatives are innovative financial products with great volatility and high investment risks.

Although BingX is committed to providing users with easy-to-use trading tools, trading itself is still a highly sophisticated field. Trading digital assets and their derivatives are subject to high market risk and price volatility and may result in partial or total loss of account funds. You must carefully consider and exercise clear judgment to evaluate your financial situation and the aforementioned risks before using BingX Services. You shall be responsible for all losses arising therefrom. If necessary, please consult relevant professionals to make informed decisions before investing. By accessing, downloading, using or clicking on "I agree" to accept any BingX Services provided by BingX, you agree that you have read, understood and accepted all of the terms and conditions stipulated in BingX Terms of Use as well as our Privacy Policy.


Trading by copying or replicating the trades of other traders involves a high level of risks, even when copying or replicating the top-performing traders. Past performance of a BingX community member is not a reliable indicator of his future performance. Content on BingX's trading platform is generated by members of its community and does not contain advice or recommendations by or on behalf of BingX.